Primary hepatocellular carcinoma in late stage
Conditions
Interventions
Sponsors
Shenzhen Tiandakang Gene Engineering Co., Ltd.
Eligibility
Sex/Gender
All
Age
29 Years to 73 Years
Inclusion criteria
Inclusion criteria: 1. Recurrent cancer after surgery or other therapies; 2. Histopathological diagnosis is confirmed according to AASLD standard; 3. Single focus =5cm or total foci =18 years old; 6. ECGO scores =12 weeks; 8. Without metastatic focus except the liver; 9. ANC >=1.5*10^9/L, PLT >=80*10^9/L, TBI<=1.5*upper limit of normal, ALT/AST <=2*upper limit of normal and APTT and PT are normal one week before; 10. Signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic to ADV-TK and Ganciclovir or others; 2. Severe cirrhosis (Child C), hepatatrophy, portal hypertension or serious ascites; Improper for local injection; 3. Diffuse liver cancer, cancer embolus, obstructive jaundice, liver failure and uncontrolled hepatic encephalopathy; 4. Serious coagulation abnormality and hemorrhagic tendency; 5. Serious diseases of internal medicine, recent acute myocardial infarction or acute infection; 6. Pregnant or breast-feeding women; 7. Other conditions improper for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS, TTP and survival; | — |
Countries
China
Contacts
Public ContactYuquan Wei, You Lu
Outcome results
None listed